dactinomycin
dactinomycin: 8 clinical trials tracked.
dactinomycin evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about dactinomycin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (8)
A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) Versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
Primary endpoint: Event free survival (EFS)
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
Primary endpoint: Objective response
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Primary endpoint: Failure free survival (FFS) for very low risk patients
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Primary endpoint: Event-free survival (EFS)
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Primary endpoint: Event-free survival (intermediate risk arm)
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Primary endpoint: Event-Free Survival (EFS)
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Primary endpoint: Event Free Survival Probability
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
Primary endpoint: Event Free Survival Probability